CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
emtricitabine, FTC (drug) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00196599
NCT00196599Phase 2Completed
CompareCT.gov

Pilot Study on Efficacy and Safety of a Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults. ANRS 091 MONTANA

ANRS, Emerging Infectious Diseases·interventional·Posted Sep 20, 2005·Updated Jun 15, 2026

In Brief

A Phase 2 clinical trial evaluating emtricitabine, FTC (drug), didanosine, ddI (drug), and 1 other intervention for HIV Infections and Antiretroviral Naive. Completed, across 1 site.

Detailed Summary

In 1999, when initiating antiretroviral treatment in HIV infected adults, a triple combination with protease inhibitor is recommended. Such therapy induces side effects and the number of pills may reduce therapy adherence. The aim of this study is to evaluate the efficacy and the safety of a once daily FTC, ddI, efavirenz combination, in HIV patients with CD4 cell count over 100/mm3, antiretroviral naive.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Antiretroviral Naive
CountriesFrance
CollaboratorsTriangle Pharmaceuticals, Gilead Sciences, Bristol-Myers Squibb, Dupont Applied Biosciences

Timeline

Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2005
Enrollment StartFeb 1, 1999
Study CompletionSep 1, 2004
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

emtricitabine, FTC (drug)drug

didanosine, ddI (drug)drug

efavirenz (drug)drug